Abstract 13628: Cardiovascular Toxicity Associated With Vascular Endothelial Growth Factor Receptor Inhibitors Use in Oncology: A Network Meta-Analysis of Phase 3 Clinical Trials
| Autor: | saad ullah malik, Asad Ullah Malik, Ebubechukwu Ezeh, Yury Kachynski, Kemnasom Nwanwene, Esiemoghie Akhigbe, Mackenzie Hamilton, Ameer Quadri, Russell Nogot, Maria Tria Tirona, Ellen Thompson |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Circulation. 144 |
| ISSN: | 1524-4539 0009-7322 |
| DOI: | 10.1161/circ.144.suppl_1.13628 |
| Popis: | Introduction: Which vascular endothelial growth factor receptor inhibitor (VEGFRi) is less cardiotoxic compared to others in same class is not well known. We compared cardiovascular safety profile of all FDA approved VEGFi used as chemotherapy for cancers. Methods: We performed PRISMA compliant literature search on PubMed, Embase, Cochrane, Web of Science, Scopus and Clinicaltrials.gov (inception-6/12/2021). Only phase 3 RCTs were included. Primary outcomes were hypertension (HTN), myocardial infarction (MI), heart failure (HF), conduction abnormalities, dyspnea and pedal edema. Random-effects meta-analysis (MA) was conducted followed by frequentist network meta-analysis (NMA). Results were reported as RR with 95% CI and OR with 95% credible intervals (CrI). Quality and risk of bias assessment were done using GRADE and Cochrane risk of bias assessment tools respectively. Results: This analysis included 20426 patients from 32 RCTs. There was a very high risk of HTN associated with VEGFi compared to placebo (RR: 4.36, 95% CI:3.5-5.4, I2:69%, p-value: Conclusions: VEGFi are associated with significantly higher risk of HTN compared to placebo. Among VEGFi, Lenvatinib is associated with slightly higher risk of HTN and there is no difference in risk of MI, HF, conduction abnormalities, dyspnea and pedal edema among VEGFi. Study is limited by heterogeneous patient population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|